DxS, Roche Expand KRAS Dx Distribution; ASCO Studies Support mCRC KRAS Testing

The exclusive worldwide distribution deal for its KRAS mutation test, which DxS signed with Roche, coincided this week with the American Society of Clinical Oncology’s annual meeting, at which researchers reported results from a prospective study supporting KRAS testing for all colorectal cancer patients.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.